Mirum's Atebrioz FDA Approval and Brelovitug Phase 3 Win: $1B+ Revenue Potential
MIRM sits 45% above its 52-week low of $63.232.
Summary
Mirum Pharmaceuticals announced FDA approval of Atebrioz for FOP and positive Phase 3 AZURE-1 data for brelovitug in HDV, with management estimating combined revenue potential exceeding $1.2 billion.
Key Events · Product Development and Regulatory · MIRM
-
Atebrioz FDA Approval for FOP
FDA approved Atebrioz (zilurgisertib) 100 mg once-daily for reducing heterotopic ossification in FOP patients aged 12+. Commercial launch expected October 2026 with $0 copay via MAP program.
-
Brelovitug Phase 3 Primary Endpoint Met
AZURE-1 study met primary endpoint: 56% (300 mg QW) and 45% (900 mg Q4W) achieved virologic response + ALT normalization vs 0% in delayed treatment arm (p<0.0001).
-
Phase 2b 48-Week Data Shows Deepening Suppression
HDV RNA below LLOQ increased from 45% to 80% (300 mg QW) between Weeks 24 and 48; ALT normalization rose from 45% to 55%.
-
Revenue Potential Exceeds $1.2 Billion
Management estimates brelovitug annual revenue potential >$1 billion in HDV and Atebrioz >$200 million in FOP.
Analysis · MIRM · Life Sciences
This 8-K formalizes two major catalysts: FDA approval of Atebrioz for FOP and positive Phase 3 AZURE-1 data for brelovitug in HDV. The filing adds critical new details beyond the prior press releases — full efficacy numbers (56% and 45% response rates vs 0% placebo), 48-week Phase 2b data showing deepening viral suppression, and management's revenue estimates of over $1 billion for brelovitug and over $200 million for Atebrioz. For a company with a $5.8 billion market cap and a recent $790 million quarterly loss, these approvals and data readouts represent the core value drivers. The brelovitug data positions Mirum for a BLA submission in H1 2027 with potential launch in Q4 2027, while Atebrioz becomes commercially available in October 2026.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 42.1% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIRM was trading at $91.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $63.23 to $130.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.